<?xml version="1.0" encoding="UTF-8"?>
<p id="P30">Dysregulation of MAPK signaling was identified in a previous smaller, proteomic study (
 <xref rid="R108" ref-type="bibr">Seyfried et al., 2017</xref>) but has not been clearly identified in transcriptomic studies. MAPK signaling is implicated in many pathways dysregulated in dementia, including immune (
 <xref rid="R59" ref-type="bibr">Jones and Kounatidis, 2017</xref>; 
 <xref rid="R73" ref-type="bibr">Lee and Kim, 2017</xref>; 
 <xref rid="R131" ref-type="bibr">Zhu et al., 2002</xref>), oxidative stress (
 <xref rid="R87" ref-type="bibr">Munoz and Ammit, 2010</xref>; 
 <xref rid="R109" ref-type="bibr">Shih et al., 2015</xref>), and tau hyperphosphorylation (
 <xref rid="R44" ref-type="bibr">Guise et al., 2001</xref>; 
 <xref rid="R63" ref-type="bibr">Kim and Choi, 2010</xref>; 
 <xref rid="R118" ref-type="bibr">Wang and Liu, 2008</xref>). The potential contribution of PEA-15, one of the C3 modules hubs, to AD pathogenesis has not been studied. Thus, in addition to identifying molecular disease processes previously associated with AD, proteomic co-expression analysis can identify less-established mechanisms.
</p>
